Literature DB >> 25714281

Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.

Robert M Marks1, Andrew Ryan, Elhamy R Heba, An Tang, Tanya J Wolfson, Anthony C Gamst, Claude B Sirlin, Mustafa R Bashir.   

Abstract

OBJECTIVE. The purpose of this study is to evaluate the per-patient diagnostic performance of an abbreviated gadoxetic acid-enhanced MRI protocol for hepatocellular carcinoma (HCC) surveillance. MATERIALS AND METHODS. A retrospective review identified 298 consecutive patients at risk for HCC enrolled in a gadoxetic acid-enhanced MRI-based HCC surveillance program. For each patient, the first gadoxetic acid-enhanced MRI was analyzed. To simulate an abbreviated protocol, two readers independently read two image sets per patient: set 1 consisted of T1-weighted 20-minute hepatobiliary phase and T2-weighted single-shot fast spin-echo (SSFSE) images; set 2 included diffusion-weighted imaging (DWI) and images from set 1. Image sets were scored as positive or negative according to the presence of at least one nodule 10 mm or larger that met the predetermined criteria. Agreement was assessed using Cohen kappa statistics. A composite reference standard was used to determine the diagnostic performance of each image set for each reader. RESULTS. Interreader agreement was substantial for both image sets (κ = 0.72 for both) and intrareader agreement was excellent (κ = 0.97-0.99). Reader performance for image set 1 was sensitivity of 85.7% for reader A and 79.6% for reader B, specificity of 91.2% for reader A and 95.2% for reader B, and negative predictive value of 97.0% for reader A and 96.0% for reader B. Reader performance for image set 2 was nearly identical, with only one of 298 examinations scored differently on image set 2 compared with set 1. CONCLUSION. An abbreviated MRI protocol consisting of T2-weighted SSFSE and gadoxetic acid-enhanced hepatobiliary phase has high negative predictive value and may be an acceptable method for HCC surveillance. The inclusion of a DWI sequence did not significantly alter the diagnostic performance of the abbreviated protocol.

Entities:  

Keywords:  MRI; gadoxetic acid; hepatocellular carcinoma; surveillance

Mesh:

Substances:

Year:  2015        PMID: 25714281     DOI: 10.2214/AJR.14.12986

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  39 in total

1.  Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Authors:  Ti-Yung Tseng; Jeng-Hwei Tseng; Bing-Shen Huang; Shen-Yen Lin; Chun-Bing Chen; Yi-Wen Fang; Gigin Lin; Ying-Chieh Lai
Journal:  Abdom Radiol (NY)       Date:  2021-03-20

2.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 3.  Abbreviated Magnetic Resonance Imaging for HCC Surveillance.

Authors:  Naik Vietti Violi; Kathryn J Fowler; Claude B Sirlin; Bachir Taouli
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

4.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.

Authors:  George N Ioannou; Pamela K Green; Lauren A Beste; Elijah J Mun; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

5.  Surveillance of hepatocellular carcinoma by medical imaging.

Authors:  Christoph F Dietrich; Andreas Teufel; Claude B Sirlin; Yi Dong
Journal:  Quant Imaging Med Surg       Date:  2019-11

Review 6.  Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance.

Authors:  Julie Y An; Miguel A Peña; Guilherme M Cunha; Michael T Booker; Bachir Taouli; Takeshi Yokoo; Claude B Sirlin; Kathryn J Fowler
Journal:  Radiographics       Date:  2020 Nov-Dec       Impact factor: 5.333

7.  Imaging biomarkers of diffuse liver disease: current status.

Authors:  Bachir Taouli; Filipe Caseiro Alves
Journal:  Abdom Radiol (NY)       Date:  2020-06-25

8.  Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.

Authors:  Ryan L Brunsing; Dennis H Chen; Alexandra Schlein; Tanya Wolfson; Anthony Gamst; Adrija Mamidipalli; Naik Vietti Violi; Robert M Marks; Bachir Taouli; Rohit Loomba; Yuko Kono; Claude B Sirlin
Journal:  Radiol Imaging Cancer       Date:  2019-11-29

9.  Abbreviated Gadoxetic Acid-enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation.

Authors:  Jeong Woo Kim; Chang Hee Lee; Yang Shin Park; Jongmee Lee; Kyeong Ah Kim
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

10.  Value of MRI in medicine: More than just another test?

Authors:  Edwin J R van Beek; Christiane Kuhl; Yoshimi Anzai; Patricia Desmond; Richard L Ehman; Qiyong Gong; Garry Gold; Vikas Gulani; Margaret Hall-Craggs; Tim Leiner; C C Tschoyoson Lim; James G Pipe; Scott Reeder; Caroline Reinhold; Marion Smits; Daniel K Sodickson; Clare Tempany; H Alberto Vargas; Meiyun Wang
Journal:  J Magn Reson Imaging       Date:  2018-08-25       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.